Advocacy intelligence hub — real-time data for patient organizations
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
ILARIS
Novartis Pharmaceuticals Corporation
ILARIS
(canakinumab)Orphan drugstandardNovartis Pharmaceuticals Corporation
12.1 Mechanism of Action Canakinumab is a human monoclonal anti-human IL-1β antibody of the IgG1/κ isotype. Canakinumab binds to human IL-1β and neutr...
Arcalyst
(rilonacept)Orphan drugstandardKiniksa Pharmaceuticals, Ltd.
12.1 Mechanism of Action Rilonacept is an interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) cytokine trap. Rilonacept blocks IL-1 signaling b...
Marcus Maurer, MD
Charite University, Berlin, Germany
📍 PUEBLO, CO
Robert Evans, PharmD.
Regeneron Pharmaceuticals
Sara Alehashemi, M.D., MD
National Institute of Allergy and Infectious Diseases (NIAID)
📍 BETHESDA, MD
Eric Hachulla, MD,PhD
University Hospital, Lille
Pierre Quartier
Centre Hospitalier Universitaire de Necker
Takayuki Hoshina
School of Medicine